SEELEY BRUCE J. 4
4 · CTI BIOPHARMA CORP · Filed Sep 20, 2018
Insider Transaction Report
Form 4
SEELEY BRUCE J.
EVP, Chief Commercial Officer
Transactions
- Award
Non-Qualified Stock Option (right to buy)
2018-09-18+125,000→ 125,000 totalExercise: $1.88Exp: 2028-09-18→ Common Stock (125,000 underlying)
Footnotes (1)
- [F1]The stock options will fully vest upon the Compensation Committee's certification of the European Medicines Agency approval of the Marketing Authorization Application for Pacritinib, assuming that such approval occurs no later than September 30, 2019.